摘要
目的探讨血清高迁移率族蛋白1(high-mobility group box 1,HMGB1)及白细胞介素(interleukin,IL)-6、-10、-23、-17和干扰素-γ(interferon-γ,IFN-γ)在宫颈癌中的表达情况,分析HMGB1对宫颈癌的诊断价值。方法宫颈癌患者78例为宫颈癌组,高度鳞状上皮内病变(high-grade squamous intraepithelial lesion,HSIL)患者50例为HSIL组,低度鳞状上皮内病变(low-grade squamous intraepithelial lesion,LSIL)患者48例为LSIL组,体检健康者41例为对照组;采用ELISA法检测各组血清HMGB及IL-6、-10、-23、-17和IFN-γ水平;分析血清HMGB1水平与宫颈癌患者临床病理特征的关系;采用Pearson相关分析宫颈癌患者血清HMGB1水平与各细胞因子的相关性;绘制ROC曲线,评估HMGB1对宫颈癌的诊断效能。结果血清HMGB1水平在宫颈癌组[(113.63±48.50)μg/L]、HSIL组[(46.23±13.76)μg/L]、LSIL组[(15.24±7.80)μg/L]依次降低(P<0.05),均高于对照组[(9.15±5.32)μg/L](P<0.05);FIGO分期Ⅱ期、有淋巴结转移、人类乳头瘤病毒阳性宫颈癌患者血清HMGB1水平[(143.56±27.35)、(142.58±26.84)、(119.30±45.21)μg/L]高于FIGO分期Ⅰ期[(101.12±50.10)μg/L]、无淋巴结转移[(101.53±50.55)μg/L]、人类乳头瘤病毒阴性患者[(89.85±56.01)μg/L](P<0.05);宫颈癌患者血清HMGB1水平与IL-6(r=0.536,P<0.001)、IL-10(r=0.380,P=0.001)、IL-23(r=0.420,P<0.001)及IL-17(r=0.253,P=0.025)呈正相关,与IFN-γ(r=-0.585,P<0.001)呈负相关;当HMGB1最佳截断值为25.39μg/L,诊断宫颈癌的AUC为0.988,灵敏度为92.31%,特异度为100.00%。结论血清HMGB1在宫颈癌发生、发展中起重要作用,可能与促进或抑制多种炎性因子表达有关,血清HMGB1水平可作为宫颈癌患者的辅助诊断指标。
Objective To analyze the value of high-mobility group box 1(HMGB1)to the diagnosis of cervical cancer by investigating the expressions of HMGB1,interleukin(IL)-6,IL-10,interferon-γ(IFN-γ),IL-23 and IL-17 in patients with cervical cancer.Methods The serum levels of HMGB1,IL-6,IL-10,IFN-γ,IL-23 and IL-17 were detected by ELISA in 78 patients with cervical cancer(cervical cancer group),50 patients with high-grade squamous intraepithelial lesion(HSIL)(HSIL group),48 patients with low-grade squamous intraepithelial lesion(LSIL)(LSIL group),and 41 healthy volunteers(control group).The correlation of serum HMGB1 level with clinicopathologic characteristics was analyzed in patients with cervical cancer.The correlation of serum HMGB1 with the relative cytokines was analyzed by Pearson.ROC curve was used to analyze the efficacy of HMGB1 on the diagnosis of cervical cancer.Results The serum HMGB1 level decreased gradually in turn in cervical cancer group((113.63±48.50)μg/L),HSIL group((46.23±13.76)μg/L),LSIL group((15.24±7.80)μg/L)and control group((9.15±5.32)μg/L)(P<0.05).The serum HMGB1 levels were higher in patients with FIGO phaseⅡ((143.56±27.35)μg/L),lymph node metastasis((142.58±26.84)μg/L)and HPV-positive((119.30±45.21)μg/L)than those in patients with FIGO phaseⅠ((101.12±50.10)μg/L),no lymph node metastasis((101.53±50.55)μg/L)and HPV-negative((89.85±56.01)μg/L)(P<0.05).HMGB1 level is positively correlated with the levels of IL-6(r=0.536,P<0.001),IL-10(r=0.380,P=0.001),IL-23(r=0.420,P<0.001)and IL-17(r=0.253,P=0.025),and negatively correlated with IFN-γ(r=-0.585,P<0.001).When the optimal cut-off value of HMGB1 was 25.39μg/L,the AUC for diagnosing cervical cancer was 0.988,with the sensitivity and specificity of 92.31%and 100.00%.Conclusion Serum HMGB1 plays an important role in the development and progress of cervical cancer,probably by promoting or inhibiting the expressions of various inflammatory cytokines,and it can be used as an auxiliary diagnostic marker for cervical cancer.
作者
吕双
陈志芳
祖菲娅·艾力
LYU Shuang;CHEN Zhifang;Zufeiya AILI(Department of Gynecology,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,China)
出处
《中华实用诊断与治疗杂志》
2020年第4期351-354,共4页
Journal of Chinese Practical Diagnosis and Therapy
基金
国家自然科学基金(81660475)。
